Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months.

NCT05245552 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.

NCT NCT05245552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months.
Lead sponsor
Sinovac Biotech Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
August 8, 2022
Completion date
August 4, 2023
Enrollment
217 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal influenza